The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Hi SK
I think they are in the process of listing under the ticker ACUT, which will be after consolidation (20:1), hence the $2 to $3's . Any figures/volume shown for ACUT are to test that everything is working prior to the listing. All IMHO.
It can't be far away - Will we hear of an equity raise, via a placing to the special people?? We need cash to to be a going concern!
BB
Link to Accustem Investor Relations
https://accustem.com/investors/
Hello all
Accustem website has an Investor relations sub menu the current SP OCT ACUT is $3.00
Link to Google Finance confirming this
https://www.google.com/finance/quote/ACUT:OTCMKTS
However Accustem ADR are listed as $0.13 cents !
Link to Google finance ACMSY
https://www.google.com/finance/quote/ACMSY:OTCMKTS
I have lost track with all the changes can anyone (Bluebelly ) explain what the F is going on ?
Thank in advance
StarKnight
Very good article and getting the word out there to those suffering with MS. Agree bobsson, anyone with SPMS or their carers would be chasing up this new treatment - IMHO.
BB
Excellent coverage, and the megaphone is what I was talking about earlier. Sufferers will be hammering on the door.
MS is progressive so your condition just deteriorates. I think in three months time if the results for the first two patients are still fantastic there will be a lot more than 10 or 20 sufferers hammering on the door to start the treatment. I think there is a fast track system to get super drugs to market where there is a critical need. It was done with covid vaccines. There will be formal time consuming trials but I think sufferers will demand early access to the drug.
https://www.bioworld.com/articles/516959-single-patient-data-suggest-tiziana-nose-a-better-way-with-cd3-in-ms?v=preview
'Tiziana Life Sciences Inc.’s intranasal, fully human anti-CD3 monoclonal antibody will need testing in 10 or 20 more patients to confirm the signal in secondary progressive multiple sclerosis (SPMS), but key opinion leaders on a conference call March 14 sounded optimistic as they checked out the prospect’s early efficacy.'
BB
“ they may have just improved anyway.”
From what, MS……… chat here has hit a new low
Lol
Erm, because the patient is getting better, nothing else has worked until now, and they are now taking our drug and nothing else.
I'm not implying that they are lieing.
but how can they establish that the patient is getting better because of our drug.
they may have just improved anyway.
thats the whole idea of a placebo type trial.
But yes time will tell let's hope they start a much larger trial later this year.
As you say Dunk, a proper trial would have over 100 people involved. However, are they lying about the results from one sufferer?
In time this will have more people involved. 12 months time this could be sped through due to it’s great results. It could also be cancelled. Let’s wait and see. If you want out - sell. It’s 40% up on a week ago.
I’ll hang on and probably buy more.
BB
Mine in HL is still the original amount.
thought the 20 to 1 would have appeared by now.
A proper trial is over 100 patients.
yes it shows safety but needs a much larger trial to give confidence. But nice to see sentiment coming back.
what bases on a study of 1 person
get real
thus is not a trial it's a circus trick
Attached is a new research note from Zacks SCR:
https://scr.zacks.com/news/news-details/2022/TLSA-KOL-Discussion-and-SPMS-6-Month-Results/default.aspx
BB
I feel very bullish after hearing the MS update. A wider trial that shows progressive MS is stopped in its tracks and also potentially improved, is massive. Also remember that is only one indication of Foralumab.
Agreed it has been a bit of a shambles in recent years, but this still has a good chance of being something really quite special
I think it’s our friend Sangi. He seemed to disappear just as this guy turned up
any news on accustem? im just pleased I got 40p ($1.01) back on some of my tizianas..
sold a load at 2.10 back in those crazy summer months, ive lost track of what that is in new money
Asia ifiltered u
AxelRose new account 10th Mar 2022 every post negative hmmm
I am not going to filter him just for the comedy value :))))
filtered - your boring YAWN!
Asia u guessed wrong
try again ramper
Looks like Sang has created a new account and posting under AxelRose
Bit of a drop on opening but we will be back over a dollar soon enough
GLA